ストックスクリーナーアプリを入手
69.75
0.36%
-0.375
前日終値:
$70.13
開ける：
$70.4
24時間の取引高:
588.34K
Relative Volume:
0.27
時価総額：
$8.16B
収益：
$947.36M
当期純損益:
$392.47M
株価収益率:
23.10
EPS:
3.02
ネットキャッシュフロー:
$392.71M
1週間 パフォーマンス:
+2.30%
1か月 パフォーマンス:
+9.01%
6か月 パフォーマンス:
+4.95%
1年 パフォーマンス:
+17.22%
1日の値動き範囲:
$69.73
$71.80
1週間の範囲:
$67.39
$71.80
52週間の値動き範囲:
$42.01
$79.50
Halozyme Therapeutics Inc Stock (HALO) Company Profile
名前
Halozyme Therapeutics Inc
セクター
電話
(858) 794-8889
住所
12390 EL CAMINO REAL, SAN DIEGO, CA
HALO を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
HALO
Halozyme Therapeutics Inc
|
69.73 | 8.00B | 947.36M | 392.47M | 392.71M | 3.02 |
|
VRTX
Vertex Pharmaceuticals Inc
|
431.15 | 106.87B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
683.40 | 68.81B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
449.02 | 58.35B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
898.58 | 53.55B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
192.84 | 40.93B | 447.02M | -1.18B | -906.14M | -6.1812 |
Halozyme Therapeutics Inc Stock (HALO) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-10-14 | アップグレード | Leerink Partners | Underperform → Market Perform |
| 2025-08-06 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2025-07-10 | 再開されました | Goldman | Neutral |
| 2025-05-14 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2025-05-13 | ダウングレード | Leerink Partners | Market Perform → Underperform |
| 2024-10-07 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2024-09-19 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2024-06-07 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2024-02-29 | 開始されました | TD Cowen | Outperform |
| 2023-07-24 | ダウングレード | Goldman | Buy → Neutral |
| 2023-07-24 | 開始されました | H.C. Wainwright | Buy |
| 2023-05-10 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2023-03-27 | 再開されました | Berenberg | Buy |
| 2023-03-16 | ダウングレード | SVB Securities | Outperform → Market Perform |
| 2022-12-21 | 再開されました | Morgan Stanley | Overweight |
| 2022-11-28 | 開始されました | Wells Fargo | Overweight |
| 2022-09-09 | 開始されました | Morgan Stanley | Overweight |
| 2022-05-23 | 開始されました | SVB Leerink | Outperform |
| 2021-06-14 | 開始されました | Evercore ISI | Outperform |
| 2021-05-17 | 開始されました | SVB Leerink | Outperform |
| 2021-05-11 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2021-01-21 | 繰り返されました | The Benchmark Company | Buy |
| 2020-12-17 | 開始されました | Berenberg | Buy |
| 2020-09-14 | 再開されました | JP Morgan | Overweight |
| 2020-07-01 | 開始されました | The Benchmark Company | Buy |
| 2020-02-05 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2020-01-09 | アップグレード | BMO Capital Markets | Market Perform → Outperform |
| 2020-01-08 | 開始されました | Goldman | Buy |
| 2019-11-05 | アップグレード | Barclays | Underweight → Equal Weight |
| 2018-10-19 | 再開されました | Piper Jaffray | Neutral |
| 2018-05-11 | ダウングレード | Barclays | Equal Weight → Underweight |
| 2018-01-24 | 開始されました | Goldman | Neutral |
| 2017-10-16 | 繰り返されました | Piper Jaffray | Overweight |
| 2017-01-06 | ダウングレード | Citigroup | Buy → Neutral |
| 2016-11-03 | 開始されました | Deutsche Bank | Buy |
| 2015-12-04 | 開始されました | Wells Fargo | Outperform |
| 2015-11-18 | 開始されました | Citigroup | Buy |
| 2015-09-22 | 開始されました | Barclays | Overweight |
| 2015-06-22 | 繰り返されました | JP Morgan | Overweight |
| 2015-03-03 | 繰り返されました | UBS | Buy |
| 2015-02-18 | 繰り返されました | MLV & Co | Buy |
| 2015-01-08 | 繰り返されました | MLV & Co | Buy |
すべてを表示
Halozyme Therapeutics Inc (HALO) 最新ニュース
How Halozyme Therapeutics Inc. (RV7) stock behaves in tightening cyclesJuly 2025 Gainers & Stepwise Trade Signal Implementation - newser.com
How Halozyme Therapeutics Inc. (RV7) stock reacts to stronger dollarQuarterly Portfolio Summary & Reliable Intraday Trade Plans - newser.com
Halozyme Therapeutics Inc RV7 Stock Analysis and ForecastHigh Dividend Yield Stocks & Small Investment Trading Plans - earlytimes.in
Strategies to average down on Halozyme Therapeutics Inc.Risk Management & Community Consensus Stock Picks - newser.com
Why Halozyme Therapeutics Inc. stock is in analyst buy zoneJuly 2025 Trade Ideas & Real-Time Market Sentiment Alerts - newser.com
Is Halozyme Therapeutics Inc. (RV7) stock good for long term investingJuly 2025 News Drivers & Expert-Curated Trade Recommendations - newser.com
Is Halozyme Therapeutics Inc. (RV7) stock nearing a technical breakout2025 Momentum Check & Smart Money Movement Tracker - newser.com
Halozyme Therapeutics, Inc. (HALO) Stock Forecasts - Yahoo Finance
Published on: 2025-11-10 03:57:54 - newser.com
A Look at Halozyme Therapeutics's Valuation Following Upbeat Q3 Earnings and Raised Full-Year Outlook - Sahm
What Halozyme Therapeutics (HALO)'s Insider Sales and Diverging Institutional Moves Mean For Shareholders - Sahm
Exit strategy if you’re trapped in Halozyme Therapeutics Inc.2025 Market WrapUp & Expert Approved Trade Ideas - newser.com
Halozyme Announces Pricing of $1.3 Billion in Notes - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Allogene Therapeutics (ALLO), Halozyme (HALO) and Progyny (PGNY) - The Globe and Mail
Halozyme Therapeutics announces proposed offering of $650M of convertible senior notes due 2031 and 2032 - MSN
Halozyme raises 2025 guidance to $1.3B–$1.375B revenue driven by royalty momentum and expands with Elektrofi acquisition - MSN
Halozyme Therapeutics prices $1.3 billion convertible notes - MSN
Latham & Watkins Advises on Halozyme Therapeutics’ Convertible Senior Notes Offerings Totaling US$1.3 Billion - Legal Desire Media and Insights
Halozyme Therapeutics down after $1.3 bln convertible bonds sale - TradingView
Will Halozyme Therapeutics Inc. stock benefit from upcoming earnings reportsMarket Weekly Review & Fast Entry High Yield Stock Tips - newser.com
Halozyme (HALO): FDA approves DARZALEX Faspro, first and only HR-SMM therapy - Stock Titan
Halozyme Therapeutics, Inc. Announces Pricing of Convertible Senior Notes - TradingView
[8-K] HALOZYME THERAPEUTICS, INC. Reports Material Event | HALO SEC FilingForm 8-K - Stock Titan
Halozyme Therapeutics Q3 2025 Earnings Preview - MSN
Developing predictive dashboards with Halozyme Therapeutics Inc. dataMarket Growth Review & Community Consensus Trade Signals - newser.com
Halozyme Therapeutics Prices $1.3 Billion Private Debt Offering - MarketScreener
Halozyme prices $1.3 billion convertible notes offering By Investing.com - Investing.com Nigeria
Halozyme prices $1.3 billion convertible notes offering - Investing.com
Will Halozyme Therapeutics Inc. stock benefit from infrastructure spendingJuly 2025 Update & Daily Price Action Insights - newser.com
Halozyme (NASDAQ: HALO) prices $1.3B convertibles; $87.20 conversion price - Stock Titan
Halozyme Therapeutics, Inc. Announces Pricing of Private Offering of $650 Million of Convertible Senior Notes due 2031 and $650 Million of Convertible Senior Notes due 2032 - PR Newswire
Will Halozyme Therapeutics Inc. price bounce be sustainableJuly 2025 Weekly Recap & Advanced Swing Trade Entry Plans - newser.com
Understanding Momentum Shifts in (HALO) - news.stocktradersdaily.com
Is Halozyme Therapeutics Inc. (RV7) stock dividend growth reliable2025 Institutional Moves & Verified Entry Point Signals - newser.com
Halozyme announces $1.3 billion convertible notes offering By Investing.com - Investing.com Australia
Halozyme Therapeutics, Inc. (HALO.MX) stock price, news, quote and history - Yahoo Finance UK
Halozyme Therapeutics, Inc. (NASDAQ:HALO) Just Released Its Third-Quarter Results And Analysts Are Updating Their Estimates - 富途牛牛
Halozyme Therapeutics, Inc. (NASDAQ:HALO) Third-Quarter Results: Here's What Analysts Are Forecasting For Next Year - simplywall.st
Published on: 2025-11-06 04:53:41 - newser.com
Halozyme Extends Credit Facility and Increases Commitments - MSN
Will Halozyme Therapeutics Inc. (RV7) stock outperform global peersWeekly Market Outlook & Low Volatility Stock Recommendations - newser.com
Renaissance Group Opens New $35M Position in Halozyme Therapeutics (NASDAQ: HALO): Why This Biotech Stock Is Worth a Look - sharewise.com
Why Halozyme Therapeutics Inc. (RV7) stock is favored by hedge funds2025 Macro Impact & Risk Controlled Daily Trade Plans - fcp.pa.gov.br
Halozyme Therapeutics, Inc. (NASDAQ:HALO) Q3 2025 Earnings Call Transcript - Insider Monkey
What insider trading reveals about Halozyme Therapeutics Inc. stockWeekly Investment Summary & Growth Oriented Trade Recommendations - newser.com
Tools to assess Halozyme Therapeutics Inc.’s risk profileFed Meeting & Weekly High Return Stock Forecasts - newser.com
Will Halozyme Therapeutics Inc. stock see PE expansionEarnings Overview Report & Risk Controlled Daily Trade Plans - newser.com
Halozyme Therapeutics Inc (HALO) 財務データ
収益
当期純利益
現金流量
EPS
Halozyme Therapeutics Inc (HALO) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Torley Helen | PRESIDENT AND CEO |
Oct 03 '25 |
Option Exercise |
8.11 |
20,000 |
162,200 |
753,719 |
| Torley Helen | PRESIDENT AND CEO |
Oct 02 '25 |
Option Exercise |
8.11 |
20,000 |
162,200 |
753,719 |
| Torley Helen | PRESIDENT AND CEO |
Oct 01 '25 |
Sale |
75.35 |
20,000 |
1,507,024 |
733,719 |
| Torley Helen | PRESIDENT AND CEO |
Oct 02 '25 |
Sale |
71.20 |
20,000 |
1,424,083 |
733,719 |
| Torley Helen | PRESIDENT AND CEO |
Oct 03 '25 |
Sale |
69.03 |
20,000 |
1,380,638 |
733,719 |
| Connaughton Bernadette | Director |
Oct 01 '25 |
Sale |
75.24 |
2,000 |
150,481 |
44,952 |
1.95%
0.82%
大文字化:
|
ボリューム (24 時間):